InterMune to Present at Thomas Weisel Partners Healthcare ... ( BRISBANE Calif. Aug. 29 /- InterM...)

InterMune to Present at Thomas Weisel Partners Healthcare Conference

Date:8/29/2008

BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in Boston on September 4, 2008 at 10:55 a.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:12/5/2009)...NSA new three-drug combination has shown in a phas...ve regimen" in the treatment of patients newly dia...ood cells in bone marrow, say researchers from Dan...r better were seen in all of the 66 patients treat...tudy, with 74 percent having a "very good partial ...

(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int

(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation

(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on

(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud

[0] Multiple myeloma patients experience high response rate with new 3-drug combination [0] Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders [0] AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign [0] Medithrive Voted #1 Medicinal Marijuana Dispensary in Bay Area [0] BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use

...ng is a statement of Matthew L. Myers, President, ...p://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOG...auds U.S. Senator Jeff Merkley (D-OR) for his lead...cts, including the authority to crack down on toba...

...ng is a Statement of Matthew L. Myers President, C...://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO...uds U.S. Senator Sherrod Brown (D-OH) for his lead...cts, including the authority to crack down on toba...

...ng is a statement of Matthew L. Myers, President, ...p://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOG...auds U.S. Senator Christopher Dodd (D-CT) for his ...roducts, including the authority to crack down on ...

...hore University HealthSystem Researcher reports in... Evanston, IL (Vocus) May 20, 2009 -- A... authored by David J. Winchester , FACS, M.D., Ch... nodes may not need a radical lymph node surgery. ...

...alance, Inc. (Nasdaq: SMBL ) today held its Annu... , Smart Balance Chairman and CEO Stephen Hughes ... and growth plans for the future. "Over the past ...es said. "We are excited as ever about the future...

...iation of Flight Attendants-CWA (AFA-CWA) today te...ose after a recent public health emergency and the...use of Representatives Subcommittee on Aviation co...elieve that we must be given the tools and ability...

Other Medicine News:Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2 Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3 Health News:Sen. Sherrod Brown Votes to Protect America's Kids from Tobacco 2 Health News:Sen. Sherrod Brown Votes to Protect America's Kids from Tobacco 3 Health News:Sen. Christopher Dodd Leads Fight to Protect America's Kids From Tobacco 2 Health News:Sen. Christopher Dodd Leads Fight to Protect America's Kids From Tobacco 3 Health News:Breast Cancer Patients May be Spared Additional Surgery 2 Health News:Breast Cancer Patients May be Spared Additional Surgery 3 Health News:Association of Flight Attendants-CWA Testifies on Emergency Planning After Recent Flu Outbreak 2

Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco Sen. Sherrod Brown Votes to Protect America's Kids from Tobacco Sen. Christopher Dodd Leads Fight to Protect America's Kids From Tobacco Breast Cancer Patients May be Spared Additional Surgery Smart Balance Holds Annual Stockholders Meeting Association of Flight Attendants-CWA Testifies on Emergency Planning After Recent Flu Outbreak

(Date:12/4/2009)DURHAM, N.C., Dec. 4 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBT) today announced that the first patient has been enrolled in the company,s Phase II-b, dose escalation, clinical trial in S

(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received

(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in

Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland 2 Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2 U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2 Wellmont Health System Awards Contract to MedQuist for Clinical Documentation Services 55426 1 Wellmont Health System Awards Contract to MedQuist for Clinical Documentation Services 55426 2 Wellmont Health System Awards Contract to MedQuist for Clinical Documentation Services 55426 3 ReBuilder Medical Technologies Inc Announces New York Marketing Agreement 55421 1 ReBuilder Medical Technologies Inc Announces New York Marketing Agreement 55421 2 PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 55418 1 PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 55418 2 PR Professionals Making Good Use of Social Media With Help From Twitter Webinars Run by BurrellesLuce 55418 3

[0] Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland [0] Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care [0] U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS

...d Acetaldehyde Levels in Subset of,Subjects with I..., Nov. 11 Raptor,Pharmaceuticals Corp. ("Raptor" ...y announced positive results in its Phase IIa stud...th ALDH2 deficiency, or ethanol,intolerance, as th...ogram.,Convivia(TM) is Raptor,s proprietary oral f...

...es patient screening for enrollment, SOUTH SAN FR...nc. (Nasdaq: RIGL ) today announced that the prev...ial of R788 (fostamatinib,disodium), the company,s...vember 2008 issue of Arthritis and Rheumatism. The...tis with a syk kinase inhibitor: A,twelve-week, ra...

Other Medicine Technology:Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program 2 Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program 3 Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program 4 Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program 5 Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism 2 Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism 3

Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...

Medicine Products:

Rapid Plasma Reagin (RPR) with MHA-TP Confirmation Ranitidine (Zantac), Serum or Plasma Quinidine Quantitative Fecal Fat

InterMune to Present at Thomas Weisel Partners Healthcare ...( BRISBANE Calif. Aug. 29 /- InterM...),Health